What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today

The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.